- Researchers investigated whether ivermectin improves clinical outcomes for hospitalized patients with COVID-19 across varying levels of disease severity.
- This international randomized controlled trial enrolled 61 critically ill and 89 noncritically ill patients across three countries.
- Critically ill patients showed an adjusted proportional odds ratio of 0.94 (95% credible interval 0.40-2.07) for organ support-free days.
- The study concluded that ivermectin was unlikely to improve the composite outcome of organ support-free days and hospital survival.
- These findings suggest that ivermectin does not provide clinical benefit for patients hospitalized with severe respiratory infections from COVID-19.
Evaluating Ivermectin in the Inpatient Management of COVID-19
The global effort to identify effective COVID-19 treatments has relied heavily on drug repurposing, a strategy that tests existing medications for new therapeutic applications to bypass lengthy development phases [1]. While certain immunomodulators and corticosteroids have successfully reduced mortality in severe cases, many other candidates have failed to show consistent clinical benefit in rigorous evaluations [2]. Ivermectin, an antiparasitic medication with hypothesized antiviral and anti-inflammatory properties, became a focal point of clinical interest despite early meta-analyses suggesting that reported benefits were often tied to studies with a high risk of bias [3, 4]. Large-scale trials in the outpatient setting have largely failed to demonstrate that ivermectin prevents progression to severe disease or reduces viral load [5, 6]. However, the potential for ivermectin to benefit patients already requiring hospitalization remained a critical question for clinicians managing high-acuity cases. A new analysis from a global, multifactorial, adaptive platform trial (a clinical trial design that allows for the simultaneous evaluation of multiple treatments and the modification of study arms based on interim data) now provides definitive evidence regarding ivermectin's lack of efficacy in the hospital setting.
Trial Design and Patient Stratification
To determine whether ivermectin improves outcomes for hospitalized patients with COVID-19, researchers utilized the Randomized, Embedded, Multifactorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP). This ongoing international study was conducted across hospitals in Pakistan, India, and Ireland between June 11, 2021, and September 9, 2022. Participants included both critically and noncritically ill patients who were randomized to receive either ivermectin or standard care without ivermectin. The primary outcome was defined as respiratory and cardiovascular organ support-free days through day 21. This metric was assessed using an ordinal scale (a statistical tool that ranks clinical outcomes in a specific order of severity), where in-hospital death was assigned a value of -1 and survivors were scored based on the actual number of days they remained free of organ support. To interpret the data, the researchers employed a Bayesian cumulative logistic model, which is a statistical framework that calculates the probability of a treatment's effect by combining prior evidence with current trial data. Ultimately, enrollment was closed for operational futility following the publication of external evidence suggesting no clinical benefit for ivermectin in nonhospitalized patients, limiting the trial's ability to reach its original recruitment targets.
Clinical Outcomes in Critically Ill Patients
In the subgroup of 61 critically ill patients, the administration of ivermectin failed to demonstrate any clinical advantage regarding survival without intensive organ support. The researchers found that the median number of organ support-free days was -1 (interquartile range [IQR], -1 to 17) for the ivermectin group, a value indicating that death was the most frequent outcome within this cohort. This result was nearly identical to the control group, which also recorded a median of -1 organ support-free days (IQR, -1 to 17.25). When evaluating the likelihood of a treatment effect, the adjusted proportional odds ratio (OR) for organ support-free days was 0.94 (95% credible interval [CrI], 0.40 to 2.07). This statistical measure suggests that the odds of achieving a better outcome on the ordinal scale were not improved by the intervention, and the posterior probability of ivermectin superiority to control was only 44.2%. The analysis of secondary endpoints further underscored the lack of efficacy in high-acuity settings. Among the critically ill participants, hospital survival was 35.1% (13/37) for those treated with ivermectin compared to 37.5% (9/24) for the control group. The adjusted OR for hospital survival in critically ill patients was 1.00 (95% CrI, 0.39 to 2.32), representing no difference in the odds of surviving to discharge between the two arms. Furthermore, the posterior probability of superiority for hospital survival was 50.0%, indicating that the treatment was no more effective than the control. For clinicians managing severe COVID-19, these data confirm that ivermectin does not provide the necessary therapeutic leverage to improve survival or reduce the requirement for mechanical ventilation and vasopressors in the intensive care unit.
Efficacy Analysis in Noncritically Ill Patients
The evaluation of ivermectin in the cohort of 89 noncritically ill patients mirrored the lack of efficacy observed in more severe cases. For these patients, the primary outcome of organ support-free days showed no meaningful difference between the study arms. The median number of organ support-free days was 22 (interquartile range [IQR], 18.5 to 22) for the ivermectin group and 22 (IQR, 16 to 22) for the control group. This resulted in an adjusted proportional odds ratio (OR) of 1.04 (95% credible interval [CrI], 0.48 to 2.34), indicating that the odds of a better clinical outcome were nearly identical regardless of treatment. The posterior probability of ivermectin superiority in noncritically ill patients was 53.7%, a value that fails to provide evidence of a therapeutic benefit over standard care. Secondary outcomes regarding hospital discharge also remained consistent with the primary findings. Hospital survival among noncritically ill patients was 84.1% (37/44) for those receiving ivermectin compared to 77.8% (35/45) for the control group. While the raw percentage was slightly higher in the treatment arm, the adjusted OR for hospital survival in noncritically ill patients was 1.16 (95% CrI, 0.5 to 3.07), demonstrating that the intervention did not significantly shift the odds of survival. The posterior probability of superiority for hospital survival was 63.3%, reinforcing the conclusion that ivermectin is unlikely to alter the clinical course for hospitalized patients even when they do not initially require intensive care. These data suggest that for clinicians treating COVID-19 on the general medical ward, ivermectin does not offer a statistically reliable advantage in preventing clinical deterioration or improving survival rates.
Implications for Inpatient Treatment Protocols
The findings from this international, multifactorial, adaptive platform, randomized, controlled trial indicate that ivermectin does not provide a clinical advantage for patients hospitalized with COVID-19. The researchers concluded that ivermectin was unlikely to improve the primary composite outcome of organ support-free days and hospital survival in both critically and noncritically ill populations. This determination led to the closure of enrollment for operational futility, particularly as external evidence increasingly suggested a lack of benefit for ivermectin in nonhospitalized patients. For clinicians managing inpatient COVID-19 cases, these results clarify that the drug does not reduce the duration of intensive respiratory or cardiovascular interventions or decrease the risk of in-hospital mortality. The statistical analysis reinforces the lack of therapeutic efficacy across different levels of disease severity. Among the 61 critically ill patients, the median number of organ support-free days was -1 (interquartile range [IQR], -1 to 17) for the ivermectin group and -1 (IQR, -1 to 17.25) for the control group, where a value of -1 signifies that death was the most common vital outcome. The adjusted proportional odds ratio (OR) was 0.94 (95% credible interval [CrI], 0.40 to 2.07), with a posterior probability of superiority to control of 44.2%. In the cohort of 89 noncritically ill patients, the adjusted proportional OR was 1.04 (95% CrI, 0.48 to 2.34), and the posterior probability of superiority was 53.7%, indicating that the odds of a better clinical outcome were essentially equivalent to standard care. Survival data further support the removal of ivermectin from inpatient treatment protocols. Among critically ill patients, hospital survival was 35.1% (13/37) for the ivermectin arm compared to 37.5% (9/24) for the control group, resulting in an adjusted OR of 1.00 (95% CrI, 0.39 to 2.32) and a posterior probability of superiority of 50.0%. For noncritically ill patients, hospital survival was 84.1% (37/44) for ivermectin and 77.8% (35/45) for control, with an adjusted OR of 1.16 (95% CrI, 0.5 to 3.07) and a posterior probability of superiority of 63.3%. Collectively, these data demonstrate that ivermectin fails to shift the clinical trajectory for hospitalized patients, regardless of whether they require intensive organ support upon admission.
References
1. Augustin Y, Staines HM, Velavan TP, Kamarulzaman A, Kremsner PG, Krishna S. Drug repurposing for COVID-19: current evidence from randomized controlled adaptive platform trials and living systematic reviews.. British medical bulletin. 2023. doi:10.1093/bmb/ldac037
2. Siemieniuk R, Bartoszko JJ, Zeraatkar D, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020. doi:10.1136/bmj.m2980
3. Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, Hernández AV. Ivermectin for the Treatment of Coronavirus Disease 2019: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Clinical Infectious Diseases. 2021. doi:10.1093/cid/ciab591
4. Helal BEH, Elgendy H, Rabie A, Ahmed H, Omran W. Role of Ivermectin in Management of Covid-19; A Systematic Review and Meta-Analysis. Ain Shams Journal of Anesthesiology. 2025. doi:10.21608/asja.2024.278348.1099
5. Bramante CT, Huling JD, Tignanelli CJ, et al. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. New England Journal of Medicine. 2022. doi:10.1056/nejmoa2201662
6. Bramante CT, Beckman KB, Mehta T, et al. Favorable Antiviral Effect of Metformin on SARS-CoV-2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of COVID-19.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2024. doi:10.1093/cid/ciae159